RecruitingNCT03723473

Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI)

Peripheral Artery Disease: Gated P-31 Magnetic Resonance Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI)

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Enrollment

40 participants

Start Date

Feb 13, 2019

Study Type

OBSERVATIONAL

Conditions

To explore the reliability of P-31 MR spectroscopy mitochondrial function in patients with peripheral arterial occlusive disease.

Min Age: 18 YearsMax Age: 70 Years

Peripheral arterial occlusive disease (PAOD) with claudication and surgery planning with proximal lesion (iliac or femoral (x-ray angiography or CT or MRA) and no distal lesions (doppler)
ABI\<0.90 or \>1.30
signed consent form
health insurance coverage

Contraindication in the practice of MRI: pacemaker, metallic cardiac valve, intra-ocular metal part, claustrophobia
critical ischemia \>15 days
Type 1 or 2 diabetes
weight \>200kg
non stabilized hypertension
beta-blockers
non-atherosclerotic vascular occlusive disease (Buerger disease, Takayasu disease, venous disease, trapped popliteal artery etc..)
Neurological pathology/non-voluntary contraction

Interested in this trial?

Get notified about updates and connect with the research team.

DEVICEMagnetic Resonance Imaging (MRI)

MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.

Chu Saint-Etienne

Saint-Etienne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT03723473